BTK and hematologic disorder: It is well known that many cancer treatments for hematological malignancies are immunosuppressive, which include cytotoxic chemotherapy, monoclonal antibodies against CD20, CD38 and CD52, calcineurin inhibitors, Mammalian Target of Rapamycin (mTOR), bortezomib and Bruton’s tyrosine kinase (BTK) inhibitors [35, 36].